December 20, 2017  |  CITRUS, Conferences, viSNE

ASH Annual Meeting Report: Key Takeaways and Developments

We were excited to attend the American Society of Hematology meeting this month in Atlanta. Despite the conference beginning with the arrival of an unexpected winter storm, many leading scientists and clinicians congregated to present and discuss cutting-edge research in hematology.

The Cytobank platform was used by many who attended and presented and we were proud to contribute to these scientific advances. Highlights for us were:

  1. A multiparametric approach, “pharmacoscopy:” (a single-cell drug-response profiling approach that utilizes IF, automated microscopy, and image analysis, as detailed by Vladimer, Snijder et al., Nat. Chem. Biol. 2017) identified targetable drug pathways in CLL patients. Interestingly, the way that these authors use image morphology to quantify cell death is similar to what Ross Marklein from the FDA’s Center for Biologics Evaluation and Research (CBER) presented at BMES using Cytobank on imaging morphology data. In our consulting services, we’re excited to work with our customers on projects that integrate multiple data types, such as this work presented at ASH.
  2. Next Generation Sequencing (NGS) and its application in the clinic today was widely discussed. Similar to high dimensional cytometry analyses, developing reproducible and efficient bioinformatics analysis pipelines was identified as a major challenge to dissecting the large volume of data generated by NGS. During the late breaking abstract session, Dr. Tim Grob, presented data from a large prospective clinical trial demonstrating that NGS MRD detection can predict relapse and survival in newly diagnosed AML.
    Challenges for clinical use of Whole Exome Sequencing presented by Dr. Haferlach
    Challenges for clinical use of Whole Exome Sequencing presented by Dr. Haferlach.

     

  3.  Cytobank in action: Numerous posters and presentations used Cytobank to investigate immune system response to cancer, dysplasia, and other blood disorders. Some examples include:

20171210_TanayaShree_presenting_Stanford-1600px
Tanaya Shree, Stanford University Medical Center, presenting “
Altered Peripheral Immune Phenotypes in Mantle Cell Lymphoma Survivors”. Here, CITRUS helped identify alterations of T cell subsets on MCL PBMC samples as compared to healthy donor samples.

20171211_IbrutinibInhibitscGVHDPathogenicPre-GerminalCenterBcellsandTfh-1600px
Bita Sahaf:
“Ibrutinib Inhibits cGVHD Pathogenic Pre-Germinal center B-cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-cells”

20171210_ThomasCoats_King'sCollegeLondon-1600px
Thomas Coats:
Neoantigens in MDS Are Associated with Two Novel CD4+ T Cell Subsets and Improved Overall Survival”

Learn more about how you can:

 

May 10, 2017  |  API, CITRUS, User Stories

Two Disciplines, One Analysis Pipeline:
Leveraging the Cytobank API to Find Biological Insights

This week we interview scientists from two different disciplines to hear how they worked together and used the Cytobank API to develop an automated pipeline to find biomarkers for several chronic Graft-versus-host disease (GVHD) outcomes.  We asked bioinformatician and Cytobank consultant Ashu Sethi to share with us her experience using the API, and Cytobank’s own Hannah Polikowsky, on behalf of Vanderbilt, how this pipeline improved her analysis workflow.

AshuHannah2 More »

March 14, 2017  |  CITRUS, Education

Getting the Most out of CITRUS Part I: Imagine What You Can Do

This CITRUSsnapshotis Part I of a blog series where Cytobank’s Director of Informatics, Katherine Drake, PhD, will discuss important aspects of using CITRUS to your full advantage. She’ll help you understand when you should use CITRUS, what makes it so powerful, and what you need to know to choose the best setup options for your data.

Since we implemented CITRUS in Cytobank last fall, many scientists have taken advantage of its automated biomarker discovery pipeline to answer questions and find predictive models across a wide range of diseases. Here, I’ll discuss its capabilities and review some examples to help you imagine how you can use CITRUS, too. More »

October 17, 2016  |  Announcements, CITRUS, Education

Reminder: Sign Up for Our CITRUS Webinar

Last Call: Register for Our CITRUS Webinar Oct 19.

Only hours remain to register for our CITRUS webinar. Don’t miss out! Join us Wednesday, October 19th at 9AM PDT for CITRUS: Applications and Insights from the Experts.

Learn more about how Cytobank’s newest tool can help you automate and accelerate biomarker discovery. Hear from our team members and a panel of experts:

  • Our Cytobank scientists will review how to get started quickly with CITRUS in Cytobank with a live demo.

More »

October 4, 2016  |  Announcements, CITRUS, Release Notes

Fresh Squeezed News: Introducing CITRUS

Automatically Identify Predictive Biomarkers with Our Newest Algorithm

citrus-newsletterimage

Why do some cancer patients respond well to immunotherapy but others do not?

Why do some people have a slow and painful recovery from surgery but others have a speedy recovery?

What are the biomarkers that can help predict these outcomes ahead of time?  

The Challenge:
High-dimensional single-cell analysis approaches are excellent for investigating such questions because many mechanisms of disease may only be visible at the single-cell level, eluding bulk analysis techniques. Emerging technologies such as high parameter fluorescence and mass cytometry, and powerful data analysis platforms like Cytobank, are providing unprecedented resolution for measuring single-cell biology. With these new technologies, a variety of specific cellular populations can be simultaneously identified, and anomalies can define different clinically relevant cohorts and serve as predictive diagnostics and prognostics.

The challenge of going from high-dimensional data to these useful findings lies in the analysis, which is often cumbersome, manual, subjective, and irreproducible. Our new version of the CITRUS algorithm aims to change that. More »